KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial.

Karola S Jering, Marianna Fontana, Olivier Lairez, Simone Longhi, Olga Azevedo, Caroline Morbach, Shaun Bender, Patrick Y Jay, John Vest, Bernard E Bulwer, Narayana Prasad, Scott D Solomon, Hicham Skali

Nat Med 31(10) 3560-3568

PMID40770082
PMCIDPMC12532587
DOI10.1038/s41591-025-03851-z
发表日期2025-08-06
入排依据:未发现恶性肿瘤人群证据。
已检查 10 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other;Extended Data Fig. 1:AI 判定为 other;Extended Data Fig. 2:AI 判定为 other;Extended Data Fig. 3:AI 判定为 other;另有 5 张未列出。
摘要

摘要

In the HELIOS-B randomized clinical trial, the RNA interference therapeutic agent vutrisiran reduced the risk of all-cause mortality and recurrent cardiovascular events among patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). In this secondary analysis of HELIOS-B, we evaluated vutrisiran's effects on echocardiographic measures of cardiac structure and function in patients with ATTR-CM receiving vutrisiran or placebo (n = 654, 93% men). At 30 months after treatment, as compared to the placebo group, vutrisiran treatment attenuated increases in mean left ventricular (LV) wall thickness (least squares mean difference: -0.4 mm; 95% confidence interval (CI): -0.8, 0.0; P = 0.03) and LV mass index (-10.6 g m-2; 95% CI: -18.0, -3.3; P < 0.01). Vutrisiran treatment also attenuated declines in LV ejection fraction (2.0%; 95% CI: 0.3, 3.7; P = 0.02), absolute global longitudinal strain (1.2%; 95% CI: 0.7, 1.7; P < 0.01) and LV stroke volume (4.1 ml; 95% CI: 1.7, 6.4; P < 0.01), and decreased both the average ratio of early diastolic transmitral flow velocity to early diastolic mitral annular tissue velocity (-2.0; 95% CI: -2.9, -1.2; P < 0.01) and the early to late diastolic transmitral flow velocities ratio (-0.3; 95% CI: -0.6, -0.0; P = 0.04), as compared to placebo. Consistent with its clinical benefits, these echocardiographic findings indicate favorable effects of vutrisiran on cardiac structure and function in patients with ATTR-CM. ClinicalTrials.gov registration: NCT04153149 .

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(10,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1. Changes in echocardiographic parameters from baseline to month 30 in the vutrisiran versus placebo groups in the overall and monotherapy populations. a–h , LS mean changes in mean LV wall thickness ( a ), LV mass index ( b ), lateral e ’ velocity ( c ), lateral E / e ’ ( d ), LVEF ( e ), absolute GLS ( f ), LV stroke volume ( g ) and RV S ’ ( h ) from baseline to month 30 for vutrisiran versus placebo for the overall and monotherapy populations. Dots represent the LS mean change from baseline to month 30 and the error bars represent the s.e.m. Sample size for each echocardiographic parameter can be found in Table 2.
非 KM Figure
Fig. 2Fig. 2. Effect of vutrisiran compared with placebo on echocardiographic parameters over time in the overall population. a–h , LS mean changes over time in mean LV wall thickness ( a ), LV mass index ( b ), lateral e ’ velocity ( c ), lateral E / e ’ ( d ), LVEF ( e ), absolute GLS ( f ), LV stroke volume ( g ) and RV S ’ ( h ) according to treatment assignment in the overall population. Error bars represent the s.e.m. Sample size for each echocardiographic parameter can be found in Table 2.
非 KM Figure
Extended Data Fig. 1Extended Data Fig. 1. Effect of Vutrisiran on Mean Left Ventricular Wall Thickness Over Time. Mean values (±SEM) during follow-up are shown according to treatment assignment in the ( a ) overall (n = 645) and ( b ) vutrisiran monotherapy population (n = 388). Error bars represent the standard error of the mean.
非 KM Figure
Extended Data Fig. 2Extended Data Fig. 2. Effect of Vutrisiran on Left Ventricular Mass Index Over Time. Mean values (±SEM) during follow-up are shown according to treatment assignment in the ( a ) overall (n = 637) and ( b ) vutrisiran monotherapy population (n = 382). Error bars represent the standard error of the mean.
非 KM Figure
Extended Data Fig. 3Extended Data Fig. 3. Effect of Vutrisiran on Lateral Early Diastolic Mitral Annular Tissue Velocity (e’) Over Time. Mean values (±SEM) during follow-up are shown according to treatment assignment in the ( a ) overall (n = 627) and ( b ) vutrisiran monotherapy population (n = 380). Error bars represent the standard error of the mean.
非 KM Figure
Extended Data Fig. 4Extended Data Fig. 4. Effect of Vutrisiran on the Ratio of Early Diastolic Transmitral Flow Velocity to Lateral Early Diastolic Mitral Annular Tissue Velocity (E/e’) Over Time. Mean values (±SEM) during follow-up are shown according to treatment assignment in the ( a ) overall (n = 620) and ( b ) vutrisiran monotherapy population (n = 321). Error bars represent the standard error of the mean.
非 KM Figure
Extended Data Fig. 5Extended Data Fig. 5. Effect of Vutrisiran on Left Ventricular Ejection Fraction Over Time. Mean values (±SEM) during follow-up are shown according to treatment assignment in the ( a ) overall (n = 627) and ( b ) vutrisiran monotherapy population (n = 374). Error bars represent the standard error of the mean.
非 KM Figure
Extended Data Fig. 6Extended Data Fig. 6. Effect of Vutrisiran on Absolute Global Longitudinal Strain Over Time. Mean values (±SEM) during follow-up are shown according to treatment assignment in the ( a ) overall (n = 652) and ( b ) vutrisiran monotherapy population (n = 393). Error bars represent the standard error of the mean.
非 KM Figure
Extended Data Fig. 7Extended Data Fig. 7. Effect of Vutrisiran on Left Ventricular Stroke Volume Over Time. Mean values (±SEM) during follow-up are shown according to treatment assignment in the ( a ) overall (n = 616) and ( b ) vutrisiran monotherapy population (n = 373). Error bars represent the standard error of the mean.
非 KM Figure
Extended Data Fig. 8Extended Data Fig. 8. Effect of Vutrisiran on Tricuspid Annular Systolic Myocardial Velocity (RV S’) Over Time. Mean values (±SEM) during follow-up are shown according to treatment assignment in the ( a ) overall (n = 625) and ( b ) vutrisiran monotherapy population (n = 374). Error bars represent the standard error of the mean.
非 KM Figure